



Innovating for  
affordable healthcare

## **Shilpa Medicare Limited**

### **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbsilpa.com, Web: www.vbsilpa.com  
CIN: L85110KA1987PLC008739

Dated: 30<sup>th</sup> June, 2020

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India  
Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.**

**Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

### **AXISHIL PRESS RELEASE ARTICLE**

#### **Shilpa Medicare Launches First Affordable Generic Drug to treat advanced kidney Cancer**

In continuation to our recent Successful Launches of Three Products in the Cancer therapy, Lenvatinib "LENSHIL®" Dasatinib "DASASHIL®" and Ibrutinib "IBRUSHIL®" in India Market, Shilpa Medicare Limited today launches the Indian branded generic of **Axitinib**, an tyrosine kinase inhibitor drug with a brand name **AXISHIL**.

AXISHIL is available as **1 mg & 5 mg tablets** in pack of 14's Tablets in one bottle.

AXISHIL is used to treat patients suffering from **Advanced Renal Cell Carcinoma (RCC)**.

This novel targeted therapy attacks cancer cells without damaging normal cells, thus causing fewer side effects. There has been a significant improvement in survival rates in patients with advanced renal cancer due to advent of this novel targeted therapy.



Innovating for  
affordable healthcare

### **Shilpa Medicare Limited**

**Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739



Currently the monthly therapy cost of innovator is approximately 1.66 Lacs and with the launch of AXISHIL, monthly cost of treatment will be reduced drastically to Rs. 14940/-.

Driving the Vision of Shilpa Medicare of "Innovating for affordable healthcare", AXISHIL is being launched to provide global quality Indian Brand with greater affordability to cancer patients. Today there are around 17,000 to 21,000 new patients in India who needs Axitinib and can be benefited by AXISHIL tablets says **Mr. Sundeip Bhatia, Business Head Formulations India.**

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**

**V V KRISHNA CHAITANYA**

**COMPANY SECRETARY**

